EA2142-Randomized Phase II Study of Platinum and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Tumors including Poorly Differentiated Neuroendocrine Carcinomas and Well-Differentiated Neuroendocrine Neoplasms
https://clinicaltrials.gov/ct2/show/NCT02595424
Cancer - Pancreatic,
Cancer - Rare
Principal Investigator: Ding Wang, MD
Gastroenteropancreatic Neuroendocrine carcinoma, pancreatic cancer, rare cancer
Accepting Participants
